Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

s perhaps one of the largest untapped pharmaceutical markets. Currently available drugs prolong the lives of patients with this condition, however, surprisingly little innovative research is being translated to new medicines. With the help of our Medical Advisory Board, we hope to demonstrate the clinical safety and efficacy of CDP-1050 in an efficient and convincing manner to the satisfaction of the medical community and regulatory authorities alike. Eventually, we hope to make the drug available to treat the desperately ill heart failure patients worldwide."

About Heart Failure

Heart failure, a condition characterized by the inability of the heart to effectively pump blood as well as by fluid accumulation in the lungs and other tissues, is suffered by an estimated five million Americans and is responsible for 300,000 deaths in the U.S. annually, according to the National Heart, Lung and Blood Institute. It is the single largest Medicare expense, at a cost of $33.2 billion each year. The five-year mortality rate with heart failure can be as high as 50 percent.

About CDP-1050

CDP-1050 is an investigational drug candidate for the treatment of heart failure. The drug is designed to correct the nitric oxide and redox imbalance in the failing heart and the cardiovascular system. CDP-1050 has a dual mechanism of action; it inhibits the production of excessive reactive oxygen radicals and restores nitric oxide to physiologic levels. The primary therapeutic target is the ryanodine receptor, the main ion channel in the heart that supplies the calcium necessary for the heart to contract. CDP-1050 is expected to enter a Phase 2 clinical trial this year.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015 Veracyte, Inc ... data demonstrating the ability of the company,s molecular ... from other interstitial lung diseases (ILDs) using samples ... potential to help thousands of patients avoid invasive, ... IPF diagnosis – a frequent challenge for physicians ...
(Date:5/20/2015)... This year has been one of the harshest ... Pearl’s Premium Ultra Low Maintenance Lawn Seed comes to ... coming out of record bad weather. Offering new ... concerns related to water, health, and climate change, Pearl's ... the standard, water-wasting, chemical-treated standard lawn. Many homeowners ...
(Date:5/20/2015)... May 20, 2015  Select Medical Corporation ("Select") ... Trade Commission granted early termination of the waiting ... of 1976, as amended, applicable to the acquisition ... a joint venture that Select has created with ... As previously announced, MJ Acquisition Corporation has signed ...
(Date:5/20/2015)... DENVER , May 20, 2015  Health ... connecting short-staffed healthcare organizations with job seekers looking ... SHIFT , a new mobile and online tool ... the healthcare industry. SHIFT enables employers ... locum tenens, travel nursing, per diem and other ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... on its flagship,suite of medication and infusion management ... and an industry-first Performance,Analytics Service that provides hospitals ... , The ... features that can help hospitals increase the security ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... in a panel,discussion at the 2008 RBC Capital Marketing Healthcare ... Rheumatology", will take,place on Wednesday, December 10, 2008 at 10:00 ... City. , To access ...
... - Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority ... patients with genotypes 2 and 3 chronic hepatitis C - ... receiving 900-mcg Albuferon had comparable rates of serious adverse events, ... peginterferon alfa-2a - , , ...
Cached Biology Technology:Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... University previously developed ion transistors for transport of both ... has now succeeded in combining both transistor types into ... electronics. An advantage of chemical circuits is ... various functions. This means that we now have new ...
... University in Sweden reveals the value of carrying two layers ... way their protective forewings actually function. These wings do not ... from the ground albeit at a cost. The ... the insect,s flying wings and body. The function of the ...
... As gardeners get busy filling tubs and borders with ... Bristol have discovered more about what makes flowers attractive to ... Society,s journal Functional Ecology , their research reveals that ... helping bees grip flowers especially when the wind gets ...
Cached Biology News:Flapping protective wings increase lift 2Blowing in the wind: How hidden flower features are crucial for bees 2
... CultureWell cell culture chambered coverslips ... cells for staining and imaging. ... silicone gaskets with standard optical-quality ... and ready to use. Preassembled ...
Vybrant® Multidrug Resistance Assay Kit...
... mL - 25 mL pipets ,Angled acrylic pipet ... standard square or round pipet cans. Constructed of 6 ... 76 mm W x 76 mm H x 289 ... Overall dimensions: 89 mm W x 406 mm H ...
...
Biology Products: